We have developed unique insights into the structure and function of MYC that have enabled the development of potent direct small molecule inhibitors.
MYC is an intrinsically disordered protein essential for virtually all cancer functions.
No direct small molecule inhibitors have been developed until now.
Starting with an In Silico screen for drug-like MYC inhibitors…
Followed up by In Vitro confirmation of MYC target engagement..
Led to In Vivo testing for efficacy and toxicity in a mouse cancer model – our Rapid In Vivo Screen
VOR-001 induces strong dose-dependent tumor regression in a Hepatocarcinoma mode
VOR-001 confers long-term tumor specific immune memory in Hepatocellular Carcinoma mode
